RedHill Biopharma (RDHL) Free Cash Flow (2012 - 2022)

RedHill Biopharma (RDHL) has 11 years of Free Cash Flow data on file, last reported at -$2.4 million in Q4 2022.

• Free Cash Flow for Q4 2022 came in at -$2.4 million, up 83.7% year-over-year; the trailing twelve-month figure through Dec 2023 was -$2.4 million (up 91.65% YoY), and the FY2025 annual result was -$7.2 million, up 19.49% from the prior year.
• Free Cash Flow grew to -$2.4 million in Q4 2022 per RDHL's latest filing, from -$6.0 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$2.4 million in Q4 2022 and troughed at -$19.0 million in Q3 2021.
• A 5-year average of -$10.8 million and a median of -$9.9 million in 2018 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2021 and 2022: Free Cash Flow plunged 111.04% in 2021, then soared 83.7% in 2022.
• A 5-year view of Free Cash Flow shows it stood at -$8.2 million in 2018, then plunged by 68.96% to -$13.8 million in 2019, then climbed by 8.53% to -$12.7 million in 2020, then slipped by 17.38% to -$14.9 million in 2021, then soared by 83.7% to -$2.4 million in 2022.
• Business Quant data shows RDHL's Free Cash Flow at -$2.4 million in Q4 2022, -$6.0 million in Q3 2022, and -$16.4 million in Q2 2022.